Search clinical trials for: BRAF Mutant

Total 1057 results

GlaxoSmithKline

Completed

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Solid Tumours

United States
GlaxoSmithKline

Completed

A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors

Cancer

Australia, United States
GlaxoSmithKline

Completed

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors

Cancer

Japan
GlaxoSmithKline

Completed

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

Cancer

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors

Cancer

United States, Australia, United Kingdom
GlaxoSmithKline

Completed

A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects (Cancer)

Cancer

United States, France
Array BioPharma

Completed

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

AML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDS

United States, Australia, Italy, Spain, France, Switzerland, United Kingdom
GlaxoSmithKline

Completed

Effect of GSK1160724 In Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

United Kingdom
Hospices Civils de Lyon

Unknown

Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies (PAIR)

Metastatic Melanoma

France
University Hospital, Rouen

Unknown

Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal Cancer (COCA-MACS)

Metastatic Colorectal Cancer | Circulating Markers

France
Academisch Medisch Centrum - Universiteit van Amsterdam...

Unknown

Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE (BICYCLE)

Pulmonary Arterial Hypertension | Congenital Heart Disease

Netherlands
GlaxoSmithKline

No longer available

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

Melanoma

France
Spanish Cooperative Group for the Treatment of...
Bayer

Terminated

Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab (PREVIUM)

Colorectal Neoplasms | Metastatic Disease

Spain
Spanish Cooperative Group for the Treatment of...

Completed

Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques (ULTRA)

Stage IV Colorectal Cancer

Spain
Hoffmann-La Roche

Completed

A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors

Neoplasms

Australia, Spain, Denmark
GlaxoSmithKline

Completed

Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

Cancer

Spain, United States
GlaxoSmithKline

Completed

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Solid Tumours

Japan
University of Aarhus

Completed

Detection of BRAF Mutation on FNAB From Papillary Thyroid Carcinoma

Papillary Thyroid Carcinoma

Denmark
Hoffmann-La Roche

Completed

An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma

Malignant Melanoma

Italy
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); National Comprehensive Cancer Network

Terminated

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Recurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma (Locally Advanced) | Stage IIC Melanoma (Locally Advanced) | Stage IV Melanoma (Limited, Resectable)

United States
Finnish Lung Cancer Group
Roche Pharma AG

Completed

Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Non-small Cell Lung Cancer

Finland
M.D. Anderson Cancer Center
Ariad Pharmaceuticals

Withdrawn

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

Leukemia | FLT3-Mutated Acute Myeloid Leukemia | FLT3-Mutated High-Risk Myelodysplastic Syndrome
Genentech, Inc.

Terminated

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Malignant Melanoma

United States
University of Utah

Withdrawn

Radiation Use During Vemurafenib Treatment

Stage IV Melanoma | BRAFV600 Mutation

United States
National Cancer Institute (NCI)
University of Chicago; City of Hope Medical Center; University of Southern California and other collaborators

Completed

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Non Small Cell Lung Carcinoma

United States
GlaxoSmithKline

Completed

Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive
European Organisation for Research and Treatment...
Sanofi

Withdrawn

Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases (BOS3)

Colorectal Cancer Metastatic | Liver Metastases | KRAS Mutated Colorectal Cancer
British Columbia Cancer Agency
BC Cancer Foundation

Completed

The Oncopanel Pilot (TOP) Study

Gastrointestinal Stromal Tumors | Colorectal Cancer Metastatic | Advanced Melanoma | Advanced Non-Small Cell Lung Carcinoma | Patients With Diagnosed Malignancies Being Considered for Clinical Trials

Canada
Verastem, Inc.

Completed

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

Lung Cancer | Non Small Cell Lung Cancer

United States
Massachusetts General Hospital

Terminated

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

Melanoma

United States
Hoffmann-La Roche

Completed

A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies

Malignant Melanoma, Neoplasms

Korea, Republic of, Brazil, United States, Canada, Cyprus
Samsung Medical Center

Completed

Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors

Refractory Solid Tumors

Korea, Republic of
Yale University
Genentech, Inc.

Completed

Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases

Melanoma

United States
Guangdong Provincial People's Hospital

Unknown

Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC (TREND)

Non-small Cell Lung Cancer | Epidermal Growth Factor Receptor

China
Guangdong Association of Clinical Trials
Guangdong Provincial People's Hospital

Completed

Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer (BRAIN)

Non Small Cell Lung Cancer | Brain Metastasis

China
Swiss Group for Clinical Cancer Research

Terminated

Cetuximab for Elderly Patients With mCRC

Metastatic Colorectal Cancer

Switzerland
GlaxoSmithKline

Completed

SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany, Netherlands, Romania, Italy, Spain, Belgium, Denmark, Estonia, Sweden, Austria, Latvia, United Kingdom, Ukraine, Russian Federation, Greece, Czech Republic, Slovenia, Norway, Lithuania, Slovakia
Chinese Academy of Sciences
Guangdong Academy of Medical Sciences; West China Hospital; Shanghai Pulmonary...

Unknown

Therapeutic Resistance Prediction of Tyrosine Kinase Inhibitors

Non-small Cell Lung Cancer

China
Array BioPharma

Terminated

LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma (LOGIC)

Melanoma

Canada, Spain, Australia, Switzerland, Germany, United States
M.D. Anderson Cancer Center
GlaxoSmithKline; Cancer Prevention Research Institute of Texas

Completed

An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor

Melanoma

United States
Cancer Institute and Hospital, Chinese Academy...

Unknown

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Carcinoma, Non-Small-Cell Lung

China
The National Center of Oncology, Azerbaijan

Unknown

Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy (CERVIPIB)

Cervical Cancer

Azerbaijan
Hoffmann-La Roche

Completed

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Malignant Melanoma, Neoplasms

Spain, New Zealand, Hungary, Serbia, Germany, Portugal, Netherlands, Greece, Australia
Hoffmann-La Roche

Completed

A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma

Malignant Melanoma

United States
Hoffmann-La Roche

Withdrawn

A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Malignant Melanoma, Neoplasms
Hoffmann-La Roche

Completed

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Malignant Melanoma, Neoplasms

Belgium, Spain, Germany, Netherlands, Finland
Genentech, Inc.

Completed

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Multiple Myeloma, Neoplasms

United States
Groupe Hospitalier Pitie-Salpetriere
Memorial Sloan Kettering Cancer Center

Unknown

Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease (LOVE)

Erdheim-Chester Disease

United States, France
NantCell, Inc.

Completed

QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma

Metastatic Colorectal Cancer

United States, Italy, France, Russian Federation, Spain, Hungary, Poland, Singapore, Hong Kong, India
Sidney Kimmel Cancer Center at Thomas Jefferson...
Genentech, Inc.

Withdrawn

Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases

Recurrent Melanoma | Stage IV Melanoma | Tumors Metastatic to Brain

3

Subscribe